Sharemaestro Newsreel

Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There?

Biogen (BIIB) is gaining attention due to recent Alzheimer's updates, including FDA approval for LEQEMBI injections and new Phase 2 data for diranersen. Despite recent positive share price momentum, the stock is considered 9% undervalued with a fair value estimated at $219 per share, …

Earnings call transcript: Novartis tops Q2 2026 forecasts as shares rise

Novartis reported a 1% net sales growth in Q2 2026, reaching $14.4 billion, with core operating income remaining flat at $5.9 billion. The company reaffirmed its full-year 2026 guidance, expecting low single-digit net sales growth and a decline in core operating income, driven by …

Grifols (GRFS) to Post Earnings on Tuesday

Earnings Snapshot: Novartis Q2 tops earnings and revenue estimates; full-year 2026 outlook reaffirmed

[https://static.seekingalpha.com/uploads/2026/7/21/saupload_Screenshot_2026-07-21_120006.png] MORE ON NOVARTIS * Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon [https://seekingalpha.com/article/4920275-novartis-pipeline-building-continues-pelacarsen-readout-coming-soon] * Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts [https://seekingalpha.com/article/4919803-novartis-hold-on-continued-generic-erosion-need-for-2nd-half-2026-catalysts] * Novartis Plays Long Game With Antares Deal - Meaning Near-Term Upside Unlikely [https://seekingalpha.com/a

Novartis beats top-line and bottom-line estimates; reaffirms FY26 outlook

* Novartis press release [https://www.novartis.com/sites/novartis_com/files/q2-2026-media-release-en.pdf] (NVS [https://seekingalpha.com/symbol/NVS]): Q2 Non-GAAP EPS of $2.41 beats by $0.26. * Revenue of $14.41B (+2.6% Y/Y) beats by $350M. * Q2 free cash flow was USD 5.6 billion (-12% USD). * FULL-YEAR 2026 GUIDANCE REAFFIRMED: Net sales expected to …

Biogen’s 11.3M-share rebound restores pressure, but the signal stops short of a fresh buy

BIIB rose 3.4% in the latest week on nearly double its 13-week volume, keeping a 45-week Trend Signal intact while Healthcare breadth remains selective.

Reading Between The Lines Of JNJ Stock’s Latest Call

Johnson & Johnson (JNJ) reported strong pharmaceutical growth, leading to a raised full-year guidance, but this masked a concerning slowdown in its MedTech division, particularly with its Abiomed heart pump business. Analysts questioned whether the booming Innovative Medicine segment can fully compensate for the …

AstraZeneca slips Monday, underperforms market

AstraZeneca PLC (AZN) shares fell 1.70% on Monday, closing at £123.80, underperforming the broader market as the FTSE 100 Index declined 0.71%. The company's stock is now 21.31% below its 52-week high of £157.32, which was reached on February 18th.

Novartis Q2 Profit Drops, Net Sales Rise; Reaffirms FY26 Guidance

(RTTNews) - Swiss pharmaceutical major Novartis AG (NVS, NOVN.SW) reported Tuesday lower profit in its second quarter, despite higher net sales and volume growth. Further, the company said it continues to expect fiscal 2026 core operating income to decline low single-digit and net sales …

Pfizer stock trades steady as recent earnings and pipeline updates frame valuation

Pfizer's stock performance reflects a transition from peak Covid-19 revenues to a diversified portfolio. The company's revenue normalized to around $58 billion after exceeding $100 billion during the pandemic, driven by declining Covid-related product sales, while its non-Covid businesses show more stable growth. Valuation …

Novartis Pharma AG

Novartis reported sales growth in Q2 2026, driven by key brands like Kisqali, Kesimpta, and Scemblix, and reaffirmed its full-year guidance for low single-digit net sales growth. The company also highlighted significant pipeline advancements, including new approvals for Rhapsido and Itvisma, and progress in …

AbbVie stock advances on a strong 2025 base

AbbVie Inc. stock is supported by its 2025 revenue of $56.33 billion and adjusted diluted EPS of $4.85, along with a quarterly dividend of $1.64 per share. The company's 2024 net revenue of $57.0 billion, a 3.7% increase from 2023, provides a strong comparison …

Lobbying Update: $920,000 of SANOFI US SERVICES INC lobbying was just disclosed

SANOFI US SERVICES INC (SNY) disclosed $920,000 in lobbying expenditures for Q2 2026, covering a wide range of issues including drug pricing, FDA regulations, and vaccine-related matters. Concurrently, an analysis of hedge fund activity shows significant changes in SNY stock holdings, with some institutions …

Merck (MRK) Declines More Than Market: Some Information for Investors

Merck (MRK) shares declined by 2.43% in the latest trading session, underperforming the broader market indexes. Despite this recent dip, the stock had seen an 11.97% gain over the past month, outperforming its sector and the S&P 500. Investors are anticipating the company's upcoming …

Johnson & Johnson’s 68-week Trend Signal absorbs a 45.9M-share down week

JNJ slipped 1.5% in the latest week, but the broader profile remains constructive, with the stock still 8.7% above its weekly Trend Line and 85.2% through its 52-week range.

Grifols stock trades steady as leverage focus follows debt reduction and 2025 outlook

Grifols stock is holding steady as the company's focus shifts to leverage reduction after successfully lowering debt and providing a positive 2025 outlook. The plasma specialist reported a rebound in operating profitability and a swing to net profit in 2024, driven by increased plasma …

Treatment-Resistant Depression Acquisitions: Eli Lilly and Company Moves to Acquire…

Eli Lilly and Company is set to acquire AtaiBeckley for approximately $2.8 billion, with an additional $1.0 billion in potential contingent value rights. This acquisition targets AtaiBeckley's pipeline of rapid-acting neuroplastogens, particularly BPL-003, a synthetic 5-MeO-DMT for treatment-resistant depression. The deal highlights a trend …

Lobbying Update: $3,160,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed

A recent lobbying disclosure reveals that Bristol-Myers Squibb Company (BMY) reported $3,160,000 in lobbying expenditures for Q2 2026, addressing issues such as drug pricing, intellectual property reform, and the Inflation Reduction Act. The article also details recent congressional stock trading, insider transactions, hedge fund …

Lobbying Update: $1,440,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed

A recent lobbying disclosure revealed that JOHNSON & JOHNSON SERVICES INC spent $1,440,000 in Q2 2026 on lobbying efforts focused on various legislative issues, including the National Defense Authorization Act, medical device electronic labeling, drug pricing, and intellectual property. The article also details recent …

Lobbying Update: $1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed

A recent Lobbying Disclosure Act filing for Q2 2026 reveals that GILEAD SCIENCES INC lobbied with $1,590,000 on issues including pharmaceuticals, intellectual property, drug pricing, and tax policy. The article also provides GILD stock trading activity by members of Congress and company insiders, as …

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers Squibb plans to construct "the most powerful AI factory in life sciences" with Nvidia's assistance, marking its expanded collaboration to enhance AI capabilities for complex pharmaceutical problems. Meanwhile, Samsung Biologics is moving to acquire PolyPeptide Group for approximately $1.8 billion, a strategic …

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ: GILD) has outperformed the market over the last 20 years with an average annual return of 11.43%. An initial investment of $100 in GILD twenty years ago would now be worth $854.46 due to compounded returns. The article highlights the significant …

Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know

Astrazeneca (AZN) experienced a more significant drop than the broader market, closing down 2.59% while the S&P 500 had a smaller loss. Over the past month, AZN's stock fell 3.45%, underperforming both the Medical sector and the S&P 500. Investors are anticipating its upcoming …

Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, …

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

Pfizer (PFE) shares dropped 1.2% in the last trading session, underperforming the broader S&P 500 and Dow. The company is set to release its Q3 earnings on August 4, 2026, with analysts expecting a decline in both EPS and revenue compared to the prior …

Claude AI Disagrees With President Trump on Eli Lilly (LLY)

President Donald Trump recently praised Eli Lily at a public event and called it "a great company" and highlighted its planned $3.5 billion investment for a manufacturing plant in Pennsylvania. However, Claude AI begs to differ from Trump. The AI agent recently sold its …

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Eli Lilly (LLY) ended the recent trading session at $1,146.90, demonstrating a -2.73% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%. The …

Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio

Merck & Co. has secured FDA approval for Lipfendra, the first oral PCSK9 inhibitor for cholesterol, offering a pill alternative to injectable treatments previously available. This development provides a needle-free option for patients who struggle to lower LDL cholesterol with statins alone, and presents …

Biogen Brings On Spur Therapeutics CEO As Legal Chief

Biogen Inc. has appointed the CEO of an overseas gene therapy company as its new legal chief, effective next month. The article highlights the new legal chief's combined legal expertise and broad experience. The full article content is behind a paywall, offering only a …

GSK plc Stock (GSK) Closed Down by 3.17% on Jul 20: Facts Behind the Movement

GSK plc (GSK) stock fell by 3.17% on July 20, driven by renewed concerns over the Zantac litigation, heightened competition in vaccine markets, rising R&D costs, and broader regulatory scrutiny in the healthcare sector. Technical indicators suggest potential selling pressure, while analysts have adjusted …

SANOFI : Gets a Neutral rating from JP Morgan

JP Morgan has reaffirmed its "Neutral" rating for Sanofi, maintaining an unchanged target price of EUR 95. This news comes amidst a broader context of European equities trading lower in the US and various other announcements related to Sanofi's drug approvals and research collaborations.

Bristol Myers Squibb is deploying NVIDIA's most powerful AI computing system to speed drug discovery

Bristol Myers Squibb is expanding its computing infrastructure by deploying a second NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems, which provides ten times greater performance per megawatt and will significantly accelerate drug discovery. This investment extends an existing three-year partnership with …

Bristol Myers Squibb Expands Partnership with Nvidia | PharmExec

Bristol Myers Squibb is significantly expanding its AI computing infrastructure through a partnership with Nvidia, aiming to create the most powerful AI factory in life sciences. This initiative will leverage Nvidia DGX SuperPOD systems to accelerate research across multiple therapeutic areas, with AI agents …

Lobbying Update: $2,270,000 of MERCK & CO INC lobbying was just disclosed

MERCK & CO INC recently disclosed $2,270,000 in lobbying expenditures for Q2 2026, focusing on drug pricing, healthcare acts like the Inflation Reduction Act, and animal health policies. The article also details recent congressional stock trades, insider trading activity with significant sales, and hedge …

Sanofi survey uncovers Type 1 diabetes misconceptions and screening gaps

A new survey commissioned by Sanofi reveals widespread misconceptions about Type 1 diabetes and significant gaps in screening. Many adults are unaware that Type 1 diabetes can manifest in adulthood and are hesitant to get screened despite identifying as at risk. The findings suggest …

Pfizer Suspends Popular Menopause Cream in India

Pfizer has temporarily suspended the distribution of its Premarin vaginal cream in India due to unspecified supply chain difficulties, significantly reducing estrogen therapy options for women. This move impacts over 620,000 units sold annually and leaves few alternatives for genitourinary syndrome of menopause in …